Floatz logo

Tas-102

Chronic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)unclassifiedPhase 2Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Chronic Phase Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB
FLUTICASONE
Virginia Commonwealth University
Phase 2BB
su011248
OHSU Knight Cancer Institute
Phase 2B
Deferasirox
City of Hope Medical Center
Phase 2CCC

View all 12 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →